GlassScriptPhysician profile
Veronica Green
NPI 1902027261
$4,998.23
in general payments reported to CMS, 2019-2025
29 companies · $1,817 in 2025
The $1,817 reported for 2025 was more than what 92% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $164 · 2022: $265 · 2023: $975 · 2024: $1,776 · 2025: $1,817.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,569.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,568.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $734.53 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $605.35 | 2022-2025 | |
| Novo Nordisk INC | $482.05 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $478.72 | 2022-2025 | Jardiance, Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $467.86 | 2023-2025 | Breztri, Airsupra, Farxiga |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $361.95 | 2025 | Caplyta |
| Glaxosmithkline, LLC. | $304.41 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $232.86 | 2023-2025 | Xifaxan |
| Amgen INC. | $175.08 | 2023-2025 | Otezla, Repatha, Otezla |
| Ardelyx, INC. | $173.75 | 2024-2025 | Ibsrela |
| Pfizer INC. | $169.77 | 2023-2025 | |
| Phathom Pharmaceuticals, INC. | $146.85 | 2024-2025 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $146.34 | 2023-2025 | Jardiance, Synjardy |
| Lundbeck LLC | $101.47 | 2023-2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $97.97 | 2023-2024 | Rexulti |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $49.95 | 2024 | |
| Exact Sciences Corporation | $40.58 | 2024-2025 | Cologuard Collection Kit |
| Astellas Pharma US INC | $33.99 | 2024 | Veozah |
| Kowa Pharmaceuticals America, INC. | $31.55 | 2023 | Seglentis |
| Takeda Pharmaceuticals U.S.A., INC. | $22.28 | 2023 | Trintellix |
| Esperion Therapeutics, INC. | $18.63 | 2025 | Nexletol |
| Sanofi-Aventis U.S. LLC | $18.38 | 2023 | |
| Mylan Specialty L.P. | $18.02 | 2023 | Yupelri |
| Janssen Pharmaceuticals, INC | $16.55 | 2023 | Xarelto |
| Seqirus USA INC | $15.59 | 2025 | Fluad, Flucelvax |
| Biohaven Pharmaceutical Holding Company LTD. | $13.88 | 2022 | |
| Abbott Laboratories | $13.49 | 2023 | Freestyle Libre 3 |
| Athena Bioscience, LLC | $13.22 | 2023 | Nexiclon Xr |
| Currax Pharmaceuticals LLC | $13.16 | 2024 | Contrave, Onzetra Xsail |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Veronica Green listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.